The United States District Court for the Northern District of Texas has issued a decisive ruling against the Food and Drug Administration (FDA) in a significant case brought by the Public Health and Medical Professionals for Transparency (PHMPT).
The U.S. Food and Drug Administration (FDA) has paused a trial of Novavax's COVID-19-flu combination vaccine and standalone flu vaccine after a participant reported nerve damage.
An analysis recently published in the International Journal of Vaccine Theory, Practice, and Research describes the "lessons learned" from "clinical trials, mass vaccination, and censorship by the Bio-Pharmaceutical Complex," calling for a "global moratorium" on "modmRNA products until proper safety and toxicological studies are conducted."
An analysis of mRNA COVID-19 vaccines found that the inoculations skipped the "laws or regulations that we count on to protect use from potentially harmful, or deadly, medical products…"
In a recent move to address concerns about post-vaccination deaths, South Korean officials have boosted the condolence money offered to affected families.
The FDA has "repeatedly stated that effectiveness against transmission remains unproven," the trio write, noting that the agency’s website maintains: "the scientific community does not yet know if Comirnaty will reduce such transmission."
A new document from the Food and Drug Administration (FDA) stated the FDA does not "require demonstration of the prevention of infection or transmission" in order to authorize a vaccine.
